Search - tctmd.com

Displaying 221 - 240 of 652

Sort: Relevancy | Date

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

News Daily News

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

Michael O'Riordan

July 06, 2022

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

News Daily News

USPSTF: Most Vitamin, Supplement Data Still ‘Inconclusive’ on CVD Benefits

Yael L. Maxwell

June 23, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

Minorities, Poorer Patients Missing Out on Structural Heart Care

News Features TVT 2022

Minorities, Poorer Patients Missing Out on Structural Heart Care

Michael O'Riordan

June 15, 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Cocaine History? For Black Patients It Means Less Chance of Revascularization

News Conference News SCAI 2022

Cocaine History? For Black Patients It Means Less Chance of Revascularization

May 26, 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

Intravascular Imaging Boosts Outcomes in Left Main PCI ROLEX

News Conference News EuroPCR 2022

Intravascular Imaging Boosts Outcomes in Left Main PCI: ROLEX

Michael O'Riordan

May 18, 2022

Texting Tool Failed to Up Pill Adherence in ACS Patients: TEXTMEDS

News Daily News

Texting Tool Failed to Up Pill Adherence in ACS Patients: TEXTMEDS

May 10, 2022

Flu Vaccines Reduce MACE, Especially in ACS: Meta-analysis

News Daily News

Flu Vaccines Reduce MACE, Especially in ACS: Meta-analysis

Yael L. Maxwell

May 06, 2022

Streamlining EP Consult From the ER Pays Dividends in AF

News Conference News HRS 2022

Streamlining EP Consult From the ER Pays Dividends in AF

May 04, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

April 26, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

April 08, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.